Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C

NCT01903278 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

719

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis c

Interventions

DRUG: PEG-IFN-SA /RBV
DRUG: Pegasys /RBV

Sponsor

Beijing Kawin Technology Share-Holding Co., Ltd.